285 related articles for article (PubMed ID: 2460374)
21. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
22. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
23. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
24. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
25. Calmodulin and cyclic nucleotide-phosphodiesterase activities in rat mammary gland during the lactogenic cycle.
Pizarro M; Puente J; Sapag-Hagar M
FEBS Lett; 1981 Dec; 136(1):127-30. PubMed ID: 6274696
[No Abstract] [Full Text] [Related]
26. Distinct profiles of phosphodiesterase isozymes in cultured cells derived from nonpigmented and pigmented ocular ciliary epithelium.
Bode DC; Hamel LT; Wax MB
J Pharmacol Exp Ther; 1993 Dec; 267(3):1286-91. PubMed ID: 8263791
[TBL] [Abstract][Full Text] [Related]
27. [Cyclic AMP-specific nucleotide phosphodiesterase from the insoluble fraction of the human brain].
Kireeva NN; Bobruskin ID; Severin SE
Biokhimiia; 1995 May; 60(5):694-708. PubMed ID: 7662796
[TBL] [Abstract][Full Text] [Related]
28. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.
Souness JE; Brazdil R; Diocee BK; Jordan R
Br J Pharmacol; 1989 Nov; 98(3):725-34. PubMed ID: 2480168
[TBL] [Abstract][Full Text] [Related]
29. Properties of adenylate cyclase and cyclic nucleotide phosphodiesterase in hamster isolated capillary preparations.
Nemecek GM
Biochim Biophys Acta; 1980 Mar; 628(2):125-35. PubMed ID: 6244001
[TBL] [Abstract][Full Text] [Related]
30. Cyclic nucleotide phosphodiesterase activity in patients with obstructive airways disease.
Polson JB; Krzanowski JJ; Goldman AL; Szentivanyi A
Allergol Immunopathol (Madr); 1982; 10(2):101-4. PubMed ID: 6125092
[TBL] [Abstract][Full Text] [Related]
31. Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates.
Kincaid RL; Manganiello VC
Methods Enzymol; 1988; 159():457-70. PubMed ID: 2842611
[No Abstract] [Full Text] [Related]
32. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis.
Torphy TJ; Zhou HL; Burman M; Huang LB
Mol Pharmacol; 1991 Mar; 39(3):376-84. PubMed ID: 1848659
[TBL] [Abstract][Full Text] [Related]
33. The identification and characterization of two cyclic nucleotide phosphodiesterases from bovine adrenal medulla.
Sabatine JM; Coffee CJ
Arch Biochem Biophys; 1986 Aug; 249(1):95-105. PubMed ID: 3017224
[TBL] [Abstract][Full Text] [Related]
34. Properties of multiple kinetic forms of soluble cyclic nucleotide phosphodiesterase activity of rat colonic mucosa.
Craven PA; Neidig M; DeRubertis FR
Biochim Biophys Acta; 1983 May; 744(3):265-75. PubMed ID: 6303428
[TBL] [Abstract][Full Text] [Related]
35. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
Elks ML; Manganiello VC
Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
[TBL] [Abstract][Full Text] [Related]
36. Stimulation of rat liver cyclic 3':5'-nucleotide phosphodiesterase by cyclic GMP is dependent on enzyme concentration.
Guan WR; Cheung WY
Arch Biochem Biophys; 1980 Oct; 204(1):191-8. PubMed ID: 6252844
[No Abstract] [Full Text] [Related]
37. Regulation of cyclic nucleotide phosphodiesterase activity.
Vaughan M; Danello MA; Manganiello VC; Strewler GJ
Adv Cyclic Nucleotide Res; 1981; 14():263-71. PubMed ID: 6169258
[No Abstract] [Full Text] [Related]
38. Angiotensin-converting enzyme inhibition prevents myocardial infarction-induced increase in renal cortical cGMP and cAMP phosphodiesterase activities.
Clauss F; Charloux A; Piquard F; Doutreleau S; Talha S; Zoll J; Lugnier C; Geny B
Fundam Clin Pharmacol; 2015 Aug; 29(4):352-61. PubMed ID: 25939307
[TBL] [Abstract][Full Text] [Related]
39. Activation of human lymphocyte high affinity cyclic AMP phosphodiesterase by culture with 1-methyl-3-isobutylxanthine.
Thompson WJ; Ross CP; Hersh EM; Epstein PM; Strada SJ
J Cyclic Nucleotide Res; 1980; 6(1):25-36. PubMed ID: 6155390
[TBL] [Abstract][Full Text] [Related]
40. Absence of an effect of the lithium-induced increase in cyclic GMP on the cyclic GMP-stimulated phosphodiesterase (PDE II). Evidence for cyclic AMP-specific hydrolysis.
Harvey B; Carstens M; Taljaard J
Neurochem Res; 1993 Oct; 18(10):1095-100. PubMed ID: 8255358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
